Senseonics Holdings Inc (SENS) Short Interest Update
Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 25,165,859 shares, a drop of 5.3% from the December 14th total of 26,580,670 shares. Based on an average daily trading volume, of 1,514,190 shares, the days-to-cover ratio is presently 16.6 days. Currently, 27.7% of the company’s stock are sold short.
Separately, UBS Group assumed coverage on Senseonics in a research note on Tuesday, November 27th. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $6.00.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers purchased a new position in shares of Senseonics during the second quarter valued at $255,000. Bank of New York Mellon Corp lifted its position in shares of Senseonics by 336.4% in the second quarter. Bank of New York Mellon Corp now owns 163,331 shares of the company’s stock worth $671,000 after buying an additional 125,908 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Senseonics by 153.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 213,261 shares of the company’s stock worth $877,000 after buying an additional 129,089 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Senseonics in the second quarter worth about $268,000. Finally, BlackRock Inc. lifted its position in shares of Senseonics by 1,958.6% in the second quarter. BlackRock Inc. now owns 3,811,007 shares of the company’s stock worth $15,664,000 after buying an additional 3,625,877 shares during the last quarter. Institutional investors and hedge funds own 30.66% of the company’s stock.
Senseonics (NYSEAMERICAN:SENS) last announced its earnings results on Thursday, November 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $5.16 million for the quarter, compared to the consensus estimate of $5.16 million. During the same period in the previous year, the firm earned ($0.13) EPS. The firm’s revenue was up 145.7% on a year-over-year basis.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Story: Federal Reserve
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.